Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%.
週四，Labcorp（紐約證券交易所代碼：LH）報告稱，第一季度銷售額增長了4.6％，達到31.8億美元，超過了市場預期的31.2億美元。基礎業務增長6.7％。
The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign currency translation of 0.5%.
增長是由於有機收入爲2.3％，扣除資產剝離後的收購爲1.8％，外幣折算爲0.5％。
The 2.3% increase in organic revenue was driven by a 4.2% increase in the company's organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing).
有機收入增長2.3％是由該公司有機基礎業務增長4.2％推動的，但被COVID-19 聚合酶鏈反應測試（COVID-19 測試）下降（1.9％）部分抵消。
The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago.
本季度調整後的營業收入利潤率爲14.3％，與去年同期的14.7％幾乎持平。
Diagnostics Laboratories revenue for the quarter was $2.48 billion, an increase of 4.1%.
診斷實驗室本季度收入爲24.8億美元，增長4.1％。
Total volume increased by 3.4% as acquisition volume, net of divestitures contributed 2.2%, while organic volume increased by 1.2%.
總交易量增長了3.4％，扣除資產剝離後的收購量貢獻了2.2％，而有機交易量增長了1.2％。
Organic volume was up due to a 2.6% increase in the Base Business, including the negative impact from adverse weather of approximately 1%. Price/mix was up 1.9%.
有機銷量增長是由於基礎業務增長了2.6％，其中包括約1％的惡劣天氣造成的負面影響。價格/組合上漲了1.9％。
Biopharma Laboratory Services revenue reached $710.9 million, up 7.5% due to organic growth of 5.1% and foreign currency translation of 2.4%.
生物製藥實驗室服務收入達到7.109億美元，增長7.5％，這要歸因於5.1％的有機增長和2.4％的外幣折算。
Guidance: Labcorp expects 2024 adjusted EPS of $14.45-$15.35 versus prior guidance of $14.30-$15.40 and consensus of $14.82.
指導方針：Labcorp預計，2024年調整後的每股收益爲14.45美元至15.35美元，而之前的預期爲14.30美元至15.40美元，共識爲14.82美元。
Labcorp's 2024 sales are expected to increase by 4.8%-6.4% compared to prior guidance of 4.7%-6.5%, Y/Y.
Labcorp2024年的銷售額預計將增長4.8％-6.4％，而之前的預期同比增長4.7％-6.5％。
The guidance includes Diagnostics Laboratories sales growth guidance of 4.8%-6.0% and Biopharma Laboratory Services sales growth of 3.7%-5.7%, compared to prior guidance of 3.2%-4.8% and 5.5%-7.5%, respectively.
該指引包括診斷實驗室的銷售增長預期爲4.8％-6.0％，生物製藥實驗室服務的銷售增長率爲3.7％-5.7％，而之前的預期分別爲3.2％-4.8％和5.5％-7.5％。
On Wednesday, the company said it will acquire bankrupt genetic test maker Invitae Corporation (OTC:NVTA) for $239 million, a few months after the genetic test maker filed for bankruptcy.
該公司週三表示，將在該基因測試製造商申請破產幾個月後，以2.39億美元的價格收購破產的基因測試製造商Invitae Corporation（場外交易代碼：NVTA）。
Labcorp expects this transaction would generate approximately $275 million-$300 million in annual revenue, with the majority in specialty testing areas such as oncology and rare diseases.
Labcorp預計，該交易將產生約2.75億至3億美元的年收入，其中大部分來自腫瘤學和罕見疾病等專業測試領域。
William Blair suggests investors may seek clarification regarding the deal due to Invitae's increased cash burn. If Invitae can control this, the acquisition could enhance its portfolio by utilizing Labcorp's infrastructure, especially in oncology and rare diseases testing.
威廉·布萊爾表示，由於Invitae的現金消耗增加，投資者可能會尋求有關該交易的澄清。如果Invitae能夠控制這一點，那麼此次收購可以利用Labcorp的基礎設施，尤其是在腫瘤學和罕見病測試方面，來增強其投資組合。
Labcorp's aggressive M&A approach, with over $475 million spent recently, may not significantly boost segment growth but could create long-term benefits by expanding solutions and customer reach in a changing market.
Labcorp積極的併購方針，最近支出超過4.75億美元，可能不會顯著促進細分市場的增長，但可以通過在不斷變化的市場中擴大解決方案和客戶覆蓋面來創造長期收益。
Price Action: LH shares are down 4.7% at $197.86 at last check Thursday.
價格走勢：週四最後一次檢查時，LH股價下跌4.7％，至197.86美元。
Now Read: Magnificent 7 Tumble, Wipe Out $300 Billion On Meta's Weak Guidance, Q1 Stagflation Woes
立即閱讀：宏偉的7次暴跌，由於Meta的疲軟指導，第一季度滯脹困境導致3000億美元虧損
Image generated using artificial intelligence via Midjourney.
通過 Midjourney 使用人工智能生成的圖像。
譯文內容由第三人軟體翻譯。